These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Preventive monotherapy with montelukast versus DNCG in children with mild asthma. Results of and exploratory pilot study].
    Author: Liebke C, Sommerfeld C, Wahn U, Niggemann B.
    Journal: Pneumologie; 2001 May; 55(5):231-7. PubMed ID: 11449608.
    Abstract:
    BACKGROUND: Montelukast is used as an add-on medication with inhaled steroids in the therapy of childhood asthma. The aim was to determine the clinical effect of montelukast as a prophylactic therapy in mild asthma in comparison with inhaled sodium cromoglycate. METHOD: 20 children aged 6-14 years were treated in a 20-week open-labelled randomized cross-over design, starting after a 2-week run-in period with either montelukast or cromolyn for 16 weeks with a 2-week wash-out period between treatments. RESULTS: Children treated with cromoglycate showed a significant increase of FEV1 (100.6 vs. 96.5%, p < 0.01) and MEF25 (70.6 vs. 59.1%, p < 0.05) in base line lung function and after cold air challenge (FEV1 97.2 vs. 91.2%, p < 0.05; MEF25 62.9 vs. 54.4%, p < 0.01). Treatment with montelukast effected a significant increase (p < 0.05) in MEF25 from 59.1 to 67.8% in base line lung function alone. Both medications resulted in significant decreases (p < 0.05) in daytime asthma symptoms and evening peak flow variability. Comparing the two treatment substances no statistically significant differences could be registered in any endpoints including beta-agonist use. CONCLUSIONS: Both cromolyn and montelukast showed effective control of mild asthma in children; however, montelukast is more convenient in its application. Further studies are needed to determine the role of leukotriene receptor antagonists in childhood asthma.
    [Abstract] [Full Text] [Related] [New Search]